Risk of thromboembolism in patients with ALK- and EGFR-mutant lung cancer: A cohort study

Patients with ALK-mutant advanced lung adenocarcinoma have the highest rate of TE. TE is associated with worse survival across molecular subtypes. These findings should be taken into consideration in decision-making regarding thromboprophylaxis. READ ARTICLE

Journal of Thrombosis and Haemostasis DOI:doi.org/10.1111/jth.15215

Authors: Joanna Roopkumar,Shyam K. Poudel,Lorenzo Gervaso,Chandana A. Reddy,Vamsidhar Velcheti,Nathan A. Pennell,Keith R. McCrae,Alok A. Khorana

Real-World OutcomesKirk Smithanaplastic lymphocyte kinase (ALK), epidermal growth factor receptor (EGFR), molecular subtyping, non-small cell lung cancer (NSCLC), thromboembolism